Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
NCT06615557

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

Led by VistaGen Therapeutics, Inc. · Updated on 2026-04-24

236

Participants Needed

26

Research Sites

132 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-4 and choose to enter the distinct open-label extension phase of the study.

CONDITIONS

Official Title

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent provided prior to conducting any study-specific assessment.
  • Male and female adults, 18 through 65 years of age, inclusive.
  • Current diagnosis of Social Anxiety Disorder as defined in the DSM-5 and confirmed by the Mini-International Neuropsychiatric Interview (MINI).
  • Clinician-rated Liebowitz Social Anxiety Score (LSAS) total score of 70 or higher at Screening.
  • Clinician-rated Hamilton Depression Rating Scale (HAM-D) total score less than 16.
  • Female subjects of childbearing potential must commit to consistently and correctly using effective birth control throughout the study.
  • Subjects must have normal sense of smell.
Not Eligible

You will not qualify if you...

  • History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, psychosis, anorexia or bulimia, premenstrual dysphoric disorder, autism spectrum disorder, or obsessive-compulsive disorder.
  • Any other current principal or personality disorder except specific phobias or generalized anxiety disorder if not primary diagnosis.
  • Moderate or severe alcohol use disorder within 1 year before study entry or use of illicit substances or THC within 2 months before entry.
  • Significant risk of suicidal behavior or considered an imminent danger to self or others.
  • Significant nasal problems including pathology, trauma, surgery, total anosmia, or septum perforation affecting nasal chemosensory epithelium.
  • Two or more failed adequate treatment trials with approved SAD medications.
  • Currently receiving cognitive-behavioral therapy, exposure therapy, or acceptance and commitment therapy.
  • Use of psychotropic medications within 30 days before Visit 2.
  • Use of over-the-counter, prescription, off-label, CBD, or herbal anxiety treatments within 30 days before Visit 2.
  • Prior participation in a fasedienol clinical trial.
  • Participation in any other clinical trial within 30 days before or during this trial.
  • Positive urine drug screen.
  • Positive pregnancy test or currently breastfeeding unless willing to stop breastfeeding during the study.
  • Tested positive for or showed symptoms of COVID-19 within 4 weeks before screening.
  • Any clinically significant medical history or findings that could interfere with study objectives or participant safety.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 26 locations

1

Vistagen Clinical Site

Phoenix, Arizona, United States, 85012

Actively Recruiting

2

Vistagen Clinical Site

Little Rock, Arkansas, United States, 72211

Active, Not Recruiting

3

Vistagen Clinical Site

Bellflower, California, United States, 90706

Actively Recruiting

4

Vistagen Clinical Site

Oceanside, California, United States, 92056

Actively Recruiting

5

Vistagen Clinical Site

Orange, California, United States, 92868

Actively Recruiting

6

Vistagen Clinical Site

Redlands, California, United States, 92374

Active, Not Recruiting

7

Vistagen Clinical Site

Torrance, California, United States, 90504

Actively Recruiting

8

Vistagen Clinical Site

Denver, Colorado, United States, 80209

Actively Recruiting

9

Vistagen Clinical Site

Tampa, Florida, United States, 33629

Actively Recruiting

10

Vistagen Clinical Site

Decatur, Georgia, United States, 30030

Active, Not Recruiting

11

Vistagen Clinical Site

Chicago, Illinois, United States, 60640

Active, Not Recruiting

12

Vistagen Clinical Site

Naperville, Illinois, United States, 60563

Actively Recruiting

13

Vistagen Clinical Site

Boston, Massachusetts, United States, 02131

Actively Recruiting

14

Vistagen Clinical Site

Bloomfield Township, Michigan, United States, 48302

Terminated

15

Vistagen Clinical Site

Flowood, Mississippi, United States, 39232

Actively Recruiting

16

Vistagen Clinical Site

Las Vegas, Nevada, United States, 89119

Active, Not Recruiting

17

Vistagen Clinical Site

Las Vegas, Nevada, United States, 89121

Terminated

18

Vistagen Clinical Site

Albuquerque, New Mexico, United States, 87109

Actively Recruiting

19

Vistagen Clinical Site

New York, New York, United States, 10128

Actively Recruiting

20

Vistagen Clinical Site

Cincinnati, Ohio, United States, 45229

Terminated

21

Vistagen Clinical Site

Austin, Texas, United States, 78737

Actively Recruiting

22

Vistagen Clinical Site

Austin, Texas, United States, 78759

Actively Recruiting

23

Vistagen Clinical Site

Dallas, Texas, United States, 75251

Actively Recruiting

24

Vistagen Clinical Site

Houston, Texas, United States, 77055

Actively Recruiting

25

Vistagen Clinical Site

San Antonio, Texas, United States, 78229

Actively Recruiting

26

Vistagen Clinical Site

Everett, Washington, United States, 98201

Actively Recruiting

Loading map...

Research Team

C

Clinical Studies Vistagen Therapeutics, Inc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here